Join to View Full Profile
3901 Rainbow BlvdKansas City, KS 66160
Phone+1 913-588-6000
Dr. Skikne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1977 - 1979
University of the WitwatersrandClass of 1969
Certifications & Licensure
KS State Medical License 1978 - 2025
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Start of enrollment: 2007 Sep 11
- Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma Start of enrollment: 2008 Aug 12
- Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine Start of enrollment: 2012 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPhase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.Courtney D DiNardo, Rebecca Olin, Eunice S Wang, Barry Skikne, Joseph Rosenthal
Cancer Medicine. 2024-07-01 - Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the...Andrew H Wei, Gail J Roboz, Herve Dombret, Hartmut Dohner, Andre C Schuh
Haematologica. 2023-10-01 - 2 citationsPopulation Pharmacokinetics of Oral Azacitidine, and Exposure-Response Analysis in Acute Myeloid Leukemia.Allison Gaudy, Eric Laille, Rochelle Bailey, Simon Zhou, Barry Skikne
Clinical Pharmacology and Therapeutics. 2023-10-01
Abstracts/Posters
- Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...Barry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated KillingBarry S. Skikne, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Remembering James Cook, Oncology Researchers Receive 2020 NIH Director’s New Innovator Awards, and MoreFebruary 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
